CDKN1A and melanoma: In melanoma patients, CDKN1A (14%) and CDKN2A (34%) had a very high frequency of genetic aberration (inframe mutation, missense mutation, truncating mutation, amplification, deep deletion, mRNA high, mRNA low, protein high and low).